Following in the footsteps of Gilead Sciences, Merck & Co. | Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A combination of Merck’s islatravir and Gilead’s lenacapavir has
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what…
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is…
Gilead Sciences’ HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time. |…
Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started…
Some 20 years after helping introduce the first once-daily single tablet HIV regimen, Gilead Sciences has crossed the regulatory…
